Nutriband (ntrb) transdermal solutions in multi-billion dollar markets

In April 2018, the Company acquired 4P Therapeutics, a revenue-generating, third-party clinical-development specialist with a robust IP portfolio. The 4P acquisition adds Defent™ abuse-deterrent patch technology, an opioid abuse-deterrent platform for the transdermal delivery of opioid-based medications, to its development pipeline. The acquisition also adds Exenatide, a Phase 1-2 injection-free alternative for patients with Type 2 diabetes, as well as other innovative drugs and treatments in its pipeline.

Nutriband currently sells three consumer products primarily in S.Korea (Energy, Weight management and vitamin) and plans to grow its efforts in the region further into S.E Asia.

Revenue for FY 18 according to Distribution contract signed with Best Choice Inc. is projected to reach a minimum $2.1M – $4.2M in Y1 growing 10% Year over Year. Among the key growth drivers are expanding consumer product lines and ongoing development of the Company’s robust portfolio of pharmaceutical transdermal technologies. Achieving a fraction of its growth targets would provide significant improvement in shareholder value, which should be reflected in a much higher market cap long-term.

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.

The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).

Nutriband Inc. (NTRB) is a client of RedChip Companies, Inc. NTRB agreed to pay RedChip Companies, Inc. a monthly cash fee and 10,000 shares of Rule 144 stock for 6 months of RedChip investor awareness services and consulting services. RedChip also agreed to pay Small Cap Consumer Research $2,500 a month for 12 months for coverage of Nutriband, Inc. (“Subject Company”), including the publication of initiation reports, quarterly review reports, and other related research reports on the Subject Company.